MX2015015379A - Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. - Google Patents

Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.

Info

Publication number
MX2015015379A
MX2015015379A MX2015015379A MX2015015379A MX2015015379A MX 2015015379 A MX2015015379 A MX 2015015379A MX 2015015379 A MX2015015379 A MX 2015015379A MX 2015015379 A MX2015015379 A MX 2015015379A MX 2015015379 A MX2015015379 A MX 2015015379A
Authority
MX
Mexico
Prior art keywords
alpha adrenergic
subject
treatment
tissue trauma
adrenergic agonists
Prior art date
Application number
MX2015015379A
Other languages
English (en)
Inventor
Daniel W Gil
Edward C Hsia
Lydia L Andrews-Jones
Mingting Tian
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2015015379A publication Critical patent/MX2015015379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método de tratamiento de traumatismo de tejido (como daño por radiación (como radiación solar y ultravioleta), heridas, moretones, quemaduras, ampollas, excoriación, incisiones, excisiones y úlceras) en un sujeto, que comprende administrar tópicamente al área del tejido del sujeto afectado por ese traumatismo una composición que comprende una cantidad terapéuticamente eficaz de al menos un agonista alfa adrenérgico (como clorhidrato de oximetazolina) La presente invención también proporciona un método para el alivio del dolor o incomodidad asociados con cirugía estética o plástica o tratamientos cosmetológicos a un sujeto que comprende administrar dicho agonista alfa adrenérgico.
MX2015015379A 2013-05-06 2014-05-05 Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. MX2015015379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819927P 2013-05-06 2013-05-06
PCT/US2014/036778 WO2014182610A2 (en) 2013-05-06 2014-05-05 Alpha adrenergic agonists for the treatment of tissue trauma

Publications (1)

Publication Number Publication Date
MX2015015379A true MX2015015379A (es) 2016-03-04

Family

ID=50928274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015379A MX2015015379A (es) 2013-05-06 2014-05-05 Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.

Country Status (14)

Country Link
US (2) US20140329874A1 (es)
EP (1) EP2994120B1 (es)
JP (1) JP2016518409A (es)
KR (1) KR20160005351A (es)
CN (1) CN105188691A (es)
AU (1) AU2014262960A1 (es)
BR (1) BR112015027984A2 (es)
CA (1) CA2911472A1 (es)
ES (1) ES2765264T3 (es)
HK (1) HK1222558A1 (es)
MX (1) MX2015015379A (es)
RU (1) RU2015148910A (es)
SG (1) SG11201509173WA (es)
WO (1) WO2014182610A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001104A (es) * 2013-07-26 2016-08-12 Galderma Res & Dev Composiciones para tratar engrosamiento de la piel.
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
WO2017132214A1 (en) * 2016-01-26 2017-08-03 Scherer Warren J Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
WO2018074879A1 (ko) * 2016-10-21 2018-04-26 주식회사 셀버틱스 미도드린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 및/또는 고지혈증의 예방 또는 치료용 약학적 조성물
CN113197848B (zh) * 2021-05-24 2023-06-09 成都欣捷高新技术开发股份有限公司 一种重酒石酸间羟胺药物组合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1282855B (de) * 1966-08-27 1968-11-14 Merck Ag E Kosmetisches Lichtschutzmittel
US6009234A (en) * 1995-04-14 1999-12-28 Kabushiki Kaisha Toshiba Method of reproducing information
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PT1761266E (pt) * 2004-05-25 2013-06-04 Galderma Pharma Sa Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele
EP2055719A1 (en) * 2007-11-05 2009-05-06 Total Petrochemicals Research Feluy Optimisation of the ethylene polymerisation process
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
NZ601195A (en) * 2010-01-08 2015-02-27 Recro Pharma Inc Topical transdermal dexmedetomidine compositions and methods of use thereof
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
ES2618907T3 (es) * 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
US20130079379A1 (en) * 2011-07-14 2013-03-28 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Also Published As

Publication number Publication date
CN105188691A (zh) 2015-12-23
JP2016518409A (ja) 2016-06-23
EP2994120A2 (en) 2016-03-16
CA2911472A1 (en) 2014-11-13
RU2015148910A (ru) 2017-06-13
HK1222558A1 (zh) 2017-07-07
AU2014262960A1 (en) 2015-11-26
ES2765264T3 (es) 2020-06-08
US20140329874A1 (en) 2014-11-06
BR112015027984A2 (pt) 2017-09-05
SG11201509173WA (en) 2015-12-30
WO2014182610A2 (en) 2014-11-13
EP2994120B1 (en) 2019-10-09
KR20160005351A (ko) 2016-01-14
WO2014182610A3 (en) 2014-12-31
US20200054608A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
MX369385B (es) Productos para cicatrizar heridas tisulares.
NZ713621A (en) Compounds and methods of treating infections
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015015379A (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
WO2012149608A8 (en) Prenylated hydroxystilbenes
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
AU2018236629A8 (en) Hydrogel patch
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
WO2015177379A3 (en) Compositions for promoting the healing of wounds
EP3821884A4 (en) USE OF A COMPOUND IN A MEDICATION FOR THE PREVENTION, TREATMENT OR RELIEF OF PAIN
WO2018094023A3 (en) Cyclic dipeptides and wound healing
PH12015501538A1 (en) Topical ocular analgesic agents

Legal Events

Date Code Title Description
FG Grant or registration